ACELYRIN Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acelyrin Inc reports strong Q2 results, optimistic on transformative medicines

Acelyrin Inc showcased positive trial data for izokibep in HS and PsA, emphasizing transformative medicines
Company's strong financial position post-IPO and detailed responses on key program benefits
Analyst questions highlighted focus on trial timelines, differentiation, and dosing strategies
Overall positive outlook on pipeline and commitment to delivering innovative medicines

Acelyrin reports strong Q2 results, focuses on lonigutamab progress

Acelyrin Inc (SLRN) showcased positive performance in key drug programs and financial sustainability measures during Q2 2024.
While facing challenges such as workforce reductions and tinnitus cases, the company remains well-positioned for growth and clinical advancement.
Opportunities lie in engaging with regulators, sharing program updates, and leveraging their cash position for strategic expansion.
Investors can expect continued progress and transparency from Acelyrin as they navigate clinical milestones and investor engagements.

Acelyrin Inc advances lonigutamab towards Phase III, bolstered by financial strength

Acelyrin Inc's Q3 performance highlights progress in clinical development, financial stability, and strategic planning for future growth.
While facing challenges in dose announcements and study design details, the company's strengths in FDA alignment, financial flexibility, and proactive engagement present opportunities for expansion and success.
Overall, Acelyrin's positive momentum in product development and regulatory milestones positions them favorably for continued advancement and potential market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Jan. 11, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin" or "the Company") (NASDAQ: SLRN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period").

SLRN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SLRN.

ACELYRIN INVESTOR DEADLINE APPROACHING

LOS ANGELES , Jan. 11, 2024 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ACELYRIN, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Class Period: May 4, 2023 – September 11, 2023 Lead Plaintiff Deadline: January 16, 2024 If you wish to serve as lead plaintiff of the Acelyrin lawsuit, you can submit your contact information at www.glancylaw.com/cases/Acelyrin-Inc/.

SLRN Investors Have Opportunity to Lead ACELYRIN, Inc. Securities Fraud Lawsuit

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Attention Acelyrin, Inc. ("Acelyrin") (NASDAQ: SLRN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 4, 2023 and September 11, 2023. If you suffered a loss on your investment in Acelyrin, contact us about potential recovery by using the link below.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Acelyrin Investors of a Lead Plaintiff Deadline of January 16, 2024

LOS ANGELES, CA / ACCESSWIRE / January 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Acelyrin, Inc. (“Acelyrin”) (NASDAQ: SLRN). The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Acelyrin's materially misleading statements and omissions to the public,.

Final Deadline Approaching for SLRN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Class Action Lawsuit Deadline on January 16, 2024

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SLRN.

ACELYRIN INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / January 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

NEW YORK , Jan. 1, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period"), of the important January 16, 2024 lead plaintiff deadline.

ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN

RADNOR, Pa. , Dec. 29, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been against Acelyrin, Inc. ("Acelyrin") (NASDAQ: SLRN).

SLRN CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Acelyrin, Inc. (SLRN)

LOS ANGELES, CA / ACCESSWIRE / December 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

NEW YORK , Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN) and certain officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 23-cv- 09672, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period").

ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN

If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/SLRN.

ACELYRIN INVESTOR DEADLINE APPROACHING : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

ARM Holdings PLC

Instacart (Maplebear Inc.)

Cava Group, Inc.

NEXTracker Inc

Oddity Tech Ltd

RayzeBio Inc

After navigating treacherous waters in the preceding year, the US initial public offering (IPO) market embarked on a path of recovery in 2023, signaling the inception of a new upcycle.

The 2023 IPO scene: Biggest hits and misses

NEW YORK , Dec. 23, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period"), of the important January 16, 2024 lead plaintiff deadline.

ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN

LOS ANGELES, CA / ACCESSWIRE / December 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca PLC brings more than 30 years of strategic expertise in human resources, business operations, and corporate affairs alongside public board experience Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca PLC brings more than 30 years of strategic expertise in human resources, business operations, and corporate affairs alongside public board experience

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

RADNOR, Pa. , Dec. 20, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been against Acelyrin, Inc. ("Acelyrin") (NASDAQ: SLRN).

Attention SLRN Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Acelyrin, Inc. (SLRN) and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 4, 2023 and September 11, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 15, 2024.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Acelyrin, Inc. with Losses to Contact the Firm

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ACELYRIN, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 23-cv- 09672, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acelyrin securities between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACELYRIN, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN

NEW YORK , Dec. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the "Class Period"), of the important January 16, 2024 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN

ECARX Holdings Inc

Fisker Inc

Buy low, sell high. It's an investing mantra drummed into our heads from the moment we start buying stocks.

News for ACELYRIN Inc Stock (SLRN)